Image
The Frederick National Laboratory is attending the 2024 American Association for Cancer Research (AACR) annual meeting in San Diego. Our team will have a booth in the exhibitor hall to discuss partnership and job opportunities while our scientists will be giving a variety of poster presentations.
Exhibitor booth 3657
Meet representatives of our Partnership Development Office and talent recruiters at our booth in the exhibition hall daily during the conference.
- Sunday, April 7: 1-5 p.m.
- Monday, April 8: 9 a.m.-5 p.m.
- Tuesday, April 9: 9 a.m.-5 p.m.
- Wednesday, April 10: 9 a.m.-12:30 p.m.
Exhibitor Spotlight Presentation
1:30-2:30 p.m, Sunday, April 7: Spotlight Theater C - Sails Pavilion
- Session: A New Era of Discovery Power: From comprehensive microenvironment characterization to multiomic liquid biopsy
- Presenter: Li Chen, Molecular Characterization Laboratory, Frederick National Laboratory
3:45-4 p.m., Sunday, April 7: Ballroom 20 CD - Upper Level
- Session: New Drugs on the Horizon: Part 2
- Title: ND07 - BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding
- Presenter: Pedro J. Beltran, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (FNL CRADA partner)
- FNL authors attending: Anna Maciag, Dwight Nissely
Scientific posters
Stop by our scientific posters. Scientists who will be at the conference are bolded.
Sunday, April 7
1:30-5 p.m.
| Session | Title | Location | Abstract Number | FNL Authors |
|---|---|---|---|---|
| Circulating Nucleic Acids 1 | Functional characterization and a real-world clinical laboratory pilot of the Foundation for the National Institutes of Health’s (FNIH) circulating tumor DNA (ctDNA) quality control materials (QCMs) | Section 40 | 978 / 19 | Mickey Williams, Chris Karlovich, Thomas Forbes |
| Pediatric Sarcomas and Other Solid Tumors: Translational | Endogenous HiBiT-tagging of PAX3-FOXO1 reveals downregulation of the fusion oncogene by CDK inhibitors and has synergy with vincristine | Section 44 | 1089 / 10 | Chris Karlovich & Raj Chari |
| DNA Damage and Repair 1 | PI3K-AKT-mTOR signaling pathways play important roles in chromosomal instability-induced innate immune response in cancer cells | Section 17 | 411 / 11 | Pinyi Lu |
Monday, April 8
9 a.m.-12:30 p.m.
| Session | Title | Location | Abstract Number | FNL Authors |
|---|---|---|---|---|
| Liquid Biopsy and Precision Oncology | Impact of delayed processing on cfDNA quantity and quality using STRECK cfDNA tubes: Connect Pilot Study | Section 36 | 2292 / 3 | Mickey Williams, Chris Karlovich, Norma Diaz-Mayoral, Heather Cooley, Angela de Palatis, Eric Greenbank |
| Pharmacodynamic Biomarkers of Drug Response | Elucidation of the fates of CDK2 inhibited aneuploid and residual lung cancers | Section 30 | 2117 / 8 | Ethan Dmitrovsky, Liliya Tyutyunyk, Xi Liu, Kedar Narayan |
| Cell Cycle, DNA Repair, and Telomere Biology | Exploring the role of a TERT intronic tandem repeat in regulating cell proliferative responses to environmental factors and cancer risk | Section 17 | 1644 / 14 | Raj Chari |
1:30-5 p.m.
| Session | Title | Location | Abstract Number | FNL Authors |
|---|---|---|---|---|
| Animal Models of Cancer | Emergence of frameshift mutations during tumorigenesis in VCMsh2 mouse model of Lynch syndrome | Section 6 | 1445 / 16 | Yurong Song, Shaneen Baxter, Brandon Somerville, Chelsea Sanders, Ryan Baugher, Stephanie Mellott, Heidi Lawhorn, Teri Plona, Ligia Pinto |
| Late-Breaking Research: Tumor Biology 1 | Polymerase θ (POLθ) inhibitors (novobiocin, ART-558, RP6685) were tested with 22 approved and investigational agents in multi-cell type spheroids of genetically selected patient-derived human tumor cell lines | Section 54 | LB215 / 10 | Tom Dexheimer, Thomas Silvers, Nathan Coussens |
| High-Throughput Screening and New Assay Technology | Development and performance of the National Cancer Institute’s HTS384 NCI60 screen: A modernized platform to support drug discovery and development by the worldwide cancer research community | Section 20 | 3090 / 1 | Nathan Coussens, Tom Dexheimer, Eric Jones, Thomas Silvers, John Britt |
| First-in-Human Phase I Clinical Trials 1 | Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors | Section 48 | CT120 / 28 | Ralph Parchment, Apurva Srivastava, Deb Wilsker, Brandon Miller, Jeevan Govindharajulu, Will Herrick, Angie Dull, Donna Ketchum, Shaowei Li, Jiuping Ji |
| Novel Therapeutics | KIFC1 inhibition elicits antineoplastic activity in small cell lung cancer by inducing anaphase catastrophe | Section 29 | 3347 / 4 | Ethan Dmitrovsky, Xi Liu, Masanori Kawakami |
Tuesday, April 9
9:30 a.m.-12:30 p.m.
| Session | Title | Location | Abstract Number | FNL Authors |
|---|---|---|---|---|
| Integrative Computational Approaches 1 / Analytic Pipeline Optimization | Computational modeling-based discovery of novel anticancer drug candidates targeting centromere-associated protein E | Section 37 | 4945 / 10 | Pinyi Lu, Michael Weil, Naomi Ohashi, Eric Stahlberg |
| Mechanisms of Drug Resistance and Novel Combinations | Combinations of Cdc-like kinase (CLK) inhibitors with targeted oncology agents or standard chemotherapy in patient-derived multi-cell type tumor spheroids | Section 25 | 4608 / 6 | Tom Dexheimer, Thomas Silvers, Nathan Coussens |
| Immune Modulation with Cytokines | hetIL-15 and Fenofibrate combination alters the metabolic fitness of tumor-infiltrating CD8+T cells leading to TNBC tumor eradication in mice | Section 4 | 4064 / 8 | Sevasti Karaliota and Breana Myers |
| Characterization of Mutational Processes and Drivers in Cancer Development and Evolution | Insight into the structure of breakage fusion bridge events and chromothripsis in cancer cell lines using long-read sequencing | Section 15 | 4334 / 4 | Hong Lou |
| Biomarkers and Molecular Targets for Cancer Prevention | Development of self-amplifying RNA vaccines targeting prostate tissue-restricted and tumor-associated antigens | Section 31 | 4778 / 14 | Jason Marshall, Lurii Koboziev, Bradley Beckman |
1:30-5 p.m.
| Session | Title | Location | Abstract Number | FNL Authors |
|---|---|---|---|---|
| Integrative Cancer Science | The cancer omics and drug experimental response dataset (CODERData): A harmonized benchmark dataset for machine learning models of drug response prediction | Section 36 | 6210 / 13 | Michael Weil |
| Phase II Clinical Trials 2 | Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma | Section 48 | CT263 / 22 | Katherine Ferry-Galow, Ralph Parchment, Kristin Fino |
Wednesday, April 10
9 a.m.-12:30 p.m.
| Session | Title | Location | Abstract Number | FNL Authors |
|---|---|---|---|---|
| New Software Tools for Data Analysis | Improving FAIRness of computational approaches for cancer: The computational resources for cancer research portal | Section 35 | 7432 / 27 | Eric Stahlberg, Lynn Borkin, Ruth Frost, Sara Jones, Amar Khalsa, Lauren Lewis, Sunita Menon |
2024-04-07 09:00
2024-04-10 17:00
America/New_York
Meet us at AACR 2024
The Frederick National Laboratory is attending the 2024 American Association for Cancer Research (AACR) annual meeting in San Diego. Our team will have a booth in the exhibitor hall to discuss partnership and job opportunities while our scientists will be giving a variety of poster presentations. Exhibitor booth 3657 Meet representatives of our Partnership Development Office and talent recruiters at our booth in the exhibition hall daily during the conference. Sunday, April 7: 1-5 p.m. Monday, April 8: 9 a.m.-5 p.m. Tuesday, April 9: 9 a.m.-5 p.m. Wednesday, April 10: 9 a.m.-12:30 p.m ...
Frederick National Laboratory
Frederick National Laboratory